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Introduction 
 
Many gram-positive bacteria express surface proteins with ability 
to bind serum proteins [1]. The surface proteins typically contain 
tandemly repeated serum protein-binding domains with one or several 
specificities, which often include albumin binding [2,3]. The bacteria 
can thereby camouflage themselves with bound host-proteins to evade 
the immune system and potentially also scavenge protein-bound 
nutrients [4,5]. Albumin is the most abundant protein in plasma and 
expression of albumin-binding proteins has been shown to promote 
bacterial growth and virulence [5,6]. The bacterial species that express 
albumin-binding domains are usually part of the normal human flora 
and they are opportunistic pathogens. There are many different types 
of albumin-binding proteins with different size and function. For 
example, more than 40 albumin-binding domains have been found in 
one protein, forming a rod-like structure in a giant cell wall-associated 
fibronectin-binding molecule. This protein was found on the surface 
of Staphylococcus aureus and is called Ebh (ECM-binding protein 
homologue, Uniprot Q2FYJ6) [7,8]. These huge proteins, which 
have also been found on streptococci (i.e. extracellular matrix-binding 
protein (Embp), Uniprot Q8KQ73) [9], are in addition able to bind 
fibronectin. They mediate adhesion and have been shown to be 
required for biofilm formation in vivo. An additional mechanism of 
albumin  binding  was  recently  identified  when  it was  shown  that 
 
 
 
 
 
 
 
 
human serum albumin (HSA) adsorbed to bacteria could bind to and 
inactivate the antibacterial chemokine MIG/CXCL9 (monokine-
induced by gamma-interferon/CXC ligand), which is released by 
activated epithelium [10]. This albumin-dependent event protects 
from the antibacterial activity and promotes bacterial survival at the 
epithelium. Even though all functions of bacterial surface proteins are 
not yet fully elucidated, they clearly provide the bacteria expressing 
them with an evolutionary advantage. 
Streptococcal protein G (SPG), which binds to immunoglobulins 
and albumins of several species, is expressed on the surface of certain 
streptococcal strains [11-13] and is one of the best-characterized 
bacterial surface proteins. As indicated in figure 1, SPG from the 
opportunistic streptococcal strain G148 has two functional regions 
containing three immunoglobulin-binding (C1-C3) and three 
albumin-binding domains (ABD1-3), respectively [12,14]. The 
immunoglobulin-binding domains share a common four-stranded 
beta-sheet fold with a single alpha helix packed onto the sheet (4ß+α) 
[15]. Of the three homologous albumin-binding domains, the C-
terminal ABD3 has been most extensively studied; it is referred to as 
G148-ABD in the text and G148-ABD3 in figure 2A. Nuclear 
magnetic resonance (NMR) spectroscopy has established that this 46 
amino acid domain folds into a left-handed anti-parallel three-helix 
bundle (3α) [4,16], similar to the structure of the immunoglobulin-
binding domains of the well-studied staphylococcal protein A 
[17,18]. This structural element is found in several other proteins, 
which indicates that the 3α-fold is energetically and functionally 
favorable since it has been utilized broadly [19]. Interestingly, a 
structural evaluation of the repeating units in the giant albumin-
binding protein Ebh showed that its domains, one of which is 
responsible for albumin binding, are connected by a long helix that 
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participates in two three helix bundles in two adjacent repeating units 
[8]. This helix is responsible for the global rod-like structure of the 
protein. 
 
 
 
 
 
 
 
 
 
 
 
 
Historically, the most widespread use of SPG has been as a 
biotechnological tool mainly used for affinity purification of 
immunoglobulins exploiting the broad species- and subclass 
specificity of its immunoglobulin-binding domains [20,21]. Albumin-
binding regions spanning one or several albumin-binding domains, for 
example BB and ABP [22] that are indicated in figure 1, have been 
used for affinity purification or depletion of albumin [21]. Moreover, 
the use of an albumin-binding region as a fusion tag can facilitate 
affinity purification of a target protein, improve its solubility or be 
used for directed immobilization [22-24].  
Several homologous albumin-binding domains have been 
identified in surface proteins from different bacterial species. The 
sequence diversity among these is illustrated by the 16 homologues 
included in Figure 2A. Alongside G148-ABD, the so-called protein 
G-related albumin-binding (GA) module from protein PAB 
(peptostreptococcal albumin-binding) of the anaerobic bacterium 
Finegoldia magna (F. magna) has been thoroughly investigated both 
structurally and functionally [19,25,26]. Analysis of the gene 
encoding PAB suggested that its albumin-binding domain (ALB8-GA 
representing the best characterized variant, see Figure 2A) originates 
from protein G and that it was introduced as a result of an 
interspecies module-shuffling event [25]. Available data on various 
albumin-binding domains suggest a correlation between the species 
specificity of the surface proteins and the host specificity of the 
bacteria that express them [4]. G148-ABD and ALB8-GA exhibit 59 
% amino acid sequence identity, but the species specificity of G148-
ABD is much broader than for ALB8-GA whereas the binding affinity 
of ALB8-GA for HSA is roughly twofold higher. ALB8-GA has only 
been found in human isolates of F. magna and, consequently, it is 
believed to have evolved to bind HSA with higher affinity than its 
predecessor. In contrast, streptococci expressing G148-ABD have 
much broader host specificity and this domain binds albumin from 
several non-primates better than ALB8-GA [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accumulated structural data on G148-ABD [4,16] and the GA-
module [26-29] demonstrate that the domains have very similar 
tertiary structures. ALB8-GA contains an additional residue in the 
loop between the first and second helix (Figure 2A) and has a 
somewhat shorter first helix compared to G148-ABD [4]. The 
lengths and positions of the second and third helices are almost 
identical and this region also contains the most highly conserved 
sequence stretch among the homologues (Figure 2A), which implies 
that they all share a common overall fold. As would be expected, 
competitive binding studies have shown that G148-ABD and ALB8-
GA have the same binding site on HSA [4]. A crystal structure of 
ALB8-GA in complex with HSA revealed that this site is located on 
the exterior of domain II of the albumin molecule [28], figure 2B. 
The flat binding site consists of a hydrophobic center and two 
surrounding hydrogen bond networks [28]. A similar structural 
complex of ALB8-GA and a fatty acid-induced conformational form 
of HSA demonstrated that both forms could be recognized [29]. 
Mainly residues in the second helix and the following loop of G148-
ABD contribute to albumin binding, as determined by a dedicated 
mutational study [30].  
Figure 1. Schematic representation of streptococcal protein G. Protein G 
consists of an N-terminal signal sequence (Ss), an albumin-binding region 
containing three albumin-binding domains and a C-terminal 
immunoglobulin-binding region. A spacer (S) separates the binding regions 
and a C-terminal sequence (W) anchors the protein to the cell wall. 
Various albumin-binding parts, BB, ABP and the smallest albumin-binding 
unit, the 46 amino acid albumin-binding domain (G148-ABD), are 
indicated. ABD folds into a stable three-helix bundle structure (the picture 
was generated from PDB-file 1GJT). 
Figure 2A. Sequence alignment of 16 homologous albumin-binding 
domains and two engineered variants. Conserved amino acids are shown 
in gray and differences are highlighted in color. G148-ABD3 and ALB8-GA 
(sequences 1 and 2) represent the best-studied domains. PSD-1 (sequence 
17) is an engineered variant with broadened species specificity and 
ABDstable (sequence 18) is a variant that has been stabilized to alkaline 
treatment. The picture was generated in Geneious Pro version 5.5.7 
created by Biomatters and is based on a similar picture by Johansson et al. 
[4]. 
 
Figure 2B. Structure of the complex formed by ALB8-GA and HSA. The 
albumin-binding domains recognize a site located in domain II of HSA that 
does not overlap with the binding site for the neonatal Fc-receptor (FcRn), 
which plays an important role in albumin homeostasis. The picture was 
generated from PDB-file 1TF0. 
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To localize the binding site, surface exposed residues or 
combinations of residues pointing in different directions have been 
substituted with alanine and subjected to a binding analysis to HSA 
and an evaluation of secondary structure content by circular dichroism 
spectroscopy [30]. In the next step, several single residues as well as 
combinations of residues in the proximity of a functionally important 
amino acid, Tyr21 located in the second helix (Figure 2A, all 
numbering in the text is based on the numbering in this figure), were 
substituted. The corresponding variants were analyzed to determine 
the binding contributions of each residue relative the wild-type variant 
and thereby define the binding site. The most important residues were 
found to reside in the second helix and in the loop to the third helix. 
This study demonstrated that the binding of G148-ABD to HSA can 
be abolished by only a few amino acid changes and the overall 
mapped binding region in G148-ABD is largely supported by NMR-
perturbation studies performed on both the homologous ALB8-GA 
[26] and G148-ABD [4] and by the ALB8-GA:HSA structural 
complex [28]. However, the NMR-studies generally assign larger 
binding surfaces, which may in part be due to contacts between the 
albumin-binding domains, as indicated by the crystal structure of a 
dimer of ALB8-GA [27]. Neither NMR nor X-ray studies have 
specified the central importance of the second helix for binding as 
accurately as the mutational analysis of G148-ABD. 
 
 
 
 
 
 
 
 
 
Protein engineering of ABD   
 
Both G148-ABD and ALB8-GA are, despite their small size, very 
stable domains in themselves, without any additional stabilizing 
features such as bound ions or disulfide bridges. A compact 
hydrophobic core has been suggested to be responsible for the high 
melting temperature and the high tolerance to both high and low pH 
and treatment with guanidium hydrochloride [19,31,32]. Other 
attractive characteristics include a high solubility and expression level 
and an ability to refold after thermal or chemical denaturation. The 
small size also makes the domain amendable to peptide synthesis. 
These features make this three-helix bundle domain a suitable scaffold 
for further protein engineering efforts (Figure 3). Both rational and 
combinatorial approaches have been used where mutants are either 
screened individually or in large combinatorial libraries using in vitro 
selection systems such as phage display. Similar efforts, for example 
using the structurally related Z-domain [33] as a scaffold, have 
demonstrated the potential of this approach to provide molecules 
with new and/or improved characteristics [21]. 
 
Engineering of ABD to understand species specificity 
 
The well-defined sequence space that the albumin-binding 
domains represent offers an opportunity to address sequence 
determinants for their natural phenotypic variations. It has been 
proposed that a phenylalanine in position 21 of ALB8-GA (Figure 
2A) is responsible for its high affinity and specificity for HSA and 
other primate albumins, which would be mediated through an 
interaction with the hydrophobic Met329 in these albumins [28]. 
The corresponding tyrosine residue in G148-ABD can potentially 
interact more broadly with various polar or charged amino acids on 
albumins from different species. In an effort to understand such 
determinants for species specificity, a protein engineering approach 
called offset recombinant polymerase chain reaction (PCR) [34] was 
used to shuffle homologous albumin-binding sequences [34]. Seven 
so-called template domains were designed by introducing point 
mutations in G148-ABD based on the sequences of native albumin-
binding domains. Shuffling of these template sequences and 
subsequent cloning into a phage display vector generated a library that 
was screened for binders to HSA, guinea pig serum albumin (GPSA) 
or both targets in alternate rounds of selection. HSA and GPSA were 
selected as targets because ALB8-GA has a 1000-fold preference for 
binding HSA over GPSA whereas G148-ABD binds both forms with 
similar affinities [4]. In addition, the targets represent opposite ends 
of a phylogenetic tree of albumins from different species and GPSA 
contains a polar threonine residue where HSA has the non-polar 
methionine 329 [34].  
Surprisingly, all selection strategies showed a clear preference for 
the same variant, called phage-selected domain 1 (PSD-1) (Figure 
2A). PSD-1 is more similar to G148-GA than ALB8-GA on the 
sequence level and retains the Tyr21 of G148-ABD, which may partly 
explain its broad specificity. Another interesting feature of PSD-1 is 
the introduction of a lysine in position 39 (Figure 2A), a 
characteristic that is shared with ALB8-GA and also commonly found 
among the homologues. An NMR-structure of PSD-1 showed that 
this substitution stabilized the backbone in a conformation consistent 
with the albumin-bound ALB8-GA [35]. The resulting closer packing 
of the third helix in the core of PSD-1 may also explain its higher 
melting temperature (85°C) compared to G148-ABD (75°C), which 
has an isoleucine in this position [34]. Data on the dynamics of PSD-
1 also demonstrate that, since PSD-1 is less flexible than G148-ABD 
and at the same time binds phylogenetically diverse albumins more 
tightly, broad species specificity can be achieved without an increased 
backbone flexibility [35]. Previous studies have proposed that the 
backbone flexibility of G148-ABD is the reason behind its broader 
specificity compared to ALB8-GA [4]. Consequently, polymorphism 
at position 21 offers a more likely mechanism for albumin specificity 
and, in the absence of PSD-1, the relative contributions of the 
tyrosine in the binding interface and the backbone dynamics were 
difficult to asses since both features were present in G148-ABD and 
absent in ALB8-GA [35]. To further analyze the mechanism of the 
broad specificity of the rigid PSD-1, its binding to a range of 
albumins was mapped using chemical shift perturbation [36]. These 
data support the mutational mapping [30] and imply that the contacts 
along the entire length of the third helix are not as important as 
Figure 3. Engineered albumin-binding domains. Several engineered 
domains have been constructed based on G148-ABD or through shuffling 
of a set of homologous sequences. Variants mentioned in the text are 
shown together with a structural representation of the residues that have 
been randomized in three different combinatorial libraries (based on PDB-
file 1GJT). 
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indicated by the crystal complex [28]. However, small displacements 
of the third helix may lead to changes in albumin affinity that 
influence the specificity, even though PSD-1 uses essentially the same 
binding epitope to interact with phylogenetically diverse albumins 
[35,36].  
 
ABD and serum half-life 
 
Not only bacteria can benefit from albumin binding, for example 
a large number of studies have demonstrated its potential as a mean to 
achieve longer half-lives of therapeutic proteins [37]. Albumin has an 
extraordinarily long circulatory half-life of 19 days in humans as a 
result of a size above the renal filtration cutoff and a pH-dependent 
binding to the neonatal Fc-receptor (FcRn), which provides a rescue 
mechanism to divert albumin and immunoglobulin G (IgG) from a 
lysosomal degradation pathway [38]. As a consequence, non-covalent 
association to albumin can be used to extend the half-life of drugs, 
which has been investigated using several albumin-binding molecules 
including G148-ABD [39,40]. Importantly, the FcRn-binding site on 
albumin is located in domain III [41] and does not overlap or 
interfere with binding to G148-ABD [42,43] (Figure 2B).  
Inspired by the promising features of G148-ABD as a half-life 
prolonging fusion partner for protein therapeutics, it has been 
subjected to affinity maturation for HSA to enable further 
improvements of the pharmacokinetics [44]. In this effort, 15 
residues in helices two and three (Figures 3 and 4) were diversified 
followed by library selection against HSA by phage display. The 
choices of positions and randomization schemes were based on 
sequences of homologues, available structural data of G148-ABD and 
ALB8-GA and their albumin-binding residues. Two libraries were 
pooled to account for the variability caused by the extra amino acid in 
the first loop of ALB8-GA compared to G148-ABD. Sequencing 
revealed that, in as many as nine of the 15 varied positions, the wild-
type residue occurred in a majority of the selected clones. 
Interestingly, none of the selected variants originated from the sub-
library containing the additional residue in the first loop. Based on 
data from the first generation of variants, seven new domains were 
rationally constructed to share a common C-terminal segment. One of 
these new variants, ABD035 (Figure 4), had an extremely high affinity 
with an equilibrium dissociation constant (KD) for HSA of 120 fM 
[39], improved binding to albumin of several other species and 
beneficial biophysical properties [44]. ABD035, which differs from 
G148-ABD in seven positions, has several interesting sequence 
characteristics that can be related to previous studies of albumin-
binding domains. First, the preference for phenylalanine instead of 
tyrosine in position 21 correlates with the suggested importance of 
this residue for strong binding to HSA [28]. A beneficial spontaneous 
substitution at a position not variegated in the library design (I39K) 
was found in two clones and was also included in all the second-
generation variants. Interestingly, the recombined albumin-binding 
domain PSD-1 [34] described above contains the same substitution 
(Figure 2A) and other variants in the affinity maturation study 
contained I39T substitutions, which indicates that substitution of this 
position can be beneficial for binding. Surprisingly, all second-
generation variants except ABD035 were prone to aggregation. The 
high solubility of ABD035 is presumably due to a unique arginine 
residue in position 24 (Figure 4). Altogether, the more than 2000-
fold improved affinity for albumin seems to be a result of an 
optimization of both the composition of surface exposed residues and 
the structural conformation. For example, the melting temperature of 
ABD035 was higher than for a selected first generation variant but 
still significantly lower compared to G148-ABD, which indicates that 
the improved affinity does not solely result from lower entropy of the 
binding. However, a thorough structural characterization of ABD035 
is necessary to fully resolve such molecular details.  
Both G148-ABD and ABD035 have successfully been evaluated 
as half-life extending fusion partners in vivo to achieve significantly 
improved pharmacokinetics of the protein of interest [39,45]. 
Interestingly, a side-to-side comparison of ABD035, the wild-type 
G148-ABD and a weakly binding variant (G148-ABDY22A, [30]); 
representing affinities of 120 fM, 5 nM and 330 nM for HSA, 
respectively, and all within a span from 2-600 nM for mouse serum 
albumin, indicated that improved half-life could be achieved also from 
weak association to albumin [46]. This has also been shown 
previously by using peptides with weak albumin-binding affinities 
[47]. However, a study using a very low affinity variant of G148-
ABD (G148-ABDS19A, Y21A, K23A; [30] demonstrated that its affinity was 
below the threshold necessary to achieve a half-life extension [39]. 
The bacterial origin of the albumin-binding domain raises concerns 
regarding its immunogenicity, yet the bacterial proteins have evolved 
to mediate immune escape. Nevertheless, ABD035 has been subjected 
to a deimmunization strategy by substituting residues in immunogenic 
regions while maintaining the high albumin binding affinity and 
favorable biophysical characteristics [39]. Assays comparing a series of 
deimmunized variants identified a candidate, denoted ABD094, which 
in contrast to G148-ABD or ABD035 had no immunogenic potential 
in T-cell proliferation assays, where it was as inert as the control 
HSA. ABD094 is currently in multiple development programs 
(Affibody AB, unpublished data).  
 
 
 
 
 
 
 
 
 
Stabilization of ABD 
 
To improve its properties as an affinity ligand for purification or 
depletion of albumin, G148-ABD has been engineered for improved 
tolerance to alkaline conditions to withstand harsh cleaning of 
chromatographic equipment [31]. A straightforward protein 
engineering strategy, based on substituting asparagine residues that are 
susceptible to base-catalyzed deamidation with amino acids found in 
homologous sequences, resulted in a new molecule, ABDstable (Figure 
2A), with a dramatically improved stability to repeated alkaline 
exposure. Replacement of a total of four asparagine residues (N9L, 
N24D, N27D and N28K) at the same time improved the stability to 
chemical and thermal denaturation compared to G148-ABD. The 
introduction of a hydrophobic residue at a position in the first helix 
that points inwards is most likely responsible for the improved 
thermal stability (+10°C) whereas the remaining modified residues 
are surface exposed and unlikely to promote such effects [31]. 
Construction of a dimeric molecule with a stabilized linker sequence 
Figure 4. Combinatorial protein libraries based on G148-ABD and 
selected variants from them. Sequence alignment of three combinatorial 
libraries based on G148-ABD and examples of variants originating from 
them. Common residues are shown in gray and differences in color, X 
indicates randomized positions regardless of the degree or type of 
diversification used in the library design. The figure was generated with 
Geneious Pro version 5.5.7. 
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led to further improvements in alkaline stability and chromatographic 
performance [48]. 
 
Engineering new binding sites into albumin-binding domains 
 
Novel binding sites can be engineered into a protein domain to 
achieve a desired molecular recognition function while retaining the 
favorable biophysical properties of the scaffold protein. The most 
widespread three-helical protein scaffold is the Z-domain, in which 
the inherent immunoglobulin-binding site has been randomized to 
generate libraries of so called Affibody molecules that can be selected 
to bind a wide range of target proteins and provide affinity proteins 
for various applications [49]. Another similar three-helical scaffold 
that has been used for library constructions and selections is the 
Measles virus phosphoprotein P, which is a stable protein framework 
that was identified based on its structural similarity to the Z-domain 
and its encouraging physiochemical properties [50].  
G148-ABD has been used as a scaffold to generate both mono- 
[51] and bispecific [52] affinity proteins by randomization of the 
albumin-binding surface or a surface located on the opposite face of 
the molecule, respectively (Figures 3 and 4). To substitute the 
albumin-binding surface with a new binding site, eleven residues were 
identified as suitable for diversification using various in silico methods 
[51]. These residues, distributed over the last two helices and their 
interconnecting loop (Figure 4), were randomized and the library was 
screened for binders to interferon-γ using ribosome display. The 
selected molecules recognized the new target with low nanomolar 
affinities and did not have any residual binding to albumin or other 
unrelated control proteins in an enzyme-linked immunosorbent assay. 
Ten of the residues targeted for mutagenesis, all except A45, were also 
diversified during the affinity maturation of G148-ABD [44], (Figure 
4) and none of them reverted to the wild-type residue after selection 
of binders to interferon-γ, which indicates that these substitutions 
were well tolerated. Of the additional five residues that were 
diversified by Jonsson et al., one was considered non-mutable (I42) 
and the potential for diversifying the remaining four positions (S19, 
N24, K36 and D40) was not discussed further. Interestingly, three of 
these residues reverted to wild type in a majority of the clones found 
after the affinity maturation of G148-ABD (S19, N24 and I42) 
whereas K36 and D40 were substituted from wild type in several 
affinity-matured variants including ABD035 (Figure 4). However, 
more data on the contribution of each residue to the binding and 
stability of the new binding molecules are required to assess the 
general applicability of this approach. 
A more challenging approach was aimed at incorporating a novel 
binding site in G148-ABD while retaining the inherent albumin-
binding ability, thus resulting in 46 amino acid bispecific protein 
domains. The mutational mapping of the albumin-binding site in 
G148-ABD [30] suggested that as many as nine residues on the 
surface of the first and third helix could be substituted without any 
significant loss of structure, stability or HSA-binding ability. These 
residues, plus two additional surface exposed positions that displayed 
natural variation in the homologues (Y15 and A44; Figure 4), were 
randomized using the stabilized variant ABDstable [31] as a scaffold. 
Two of the total eleven randomized positions (K36 and D40 in the 
third helix) were also randomized in the G148-ABD affinity 
maturation library [44] and, while several of the remaining positions 
vary between homologues, none of them has been diversified in other 
combinatorial libraries previously. Analysis of phage stocks from 
selections against HSA by Western blot showed that albumin binding 
could be retained in the library despite the high degree of 
substitutions in the two helices [52]. The library was next subjected 
to selection against a dimeric form of the Protein A-derived Z-
domain [33]. This selection identified one variant, ABDz1 (Figure 4), 
with acquired affinity for Z (an apparent affinity of 0.4 µM) and 
retained binding to HSA. ABDz1 contains a cysteine in the beginning 
of its first helix and subsequent experiments showed that the Z-
binding was disrupted when this residue was replaced with a serine or 
when a reducing agent was present. Moreover, head-to-tail dimers of 
ABDz1C6S did not bind Z and, consequently, ABDz1 could only bind 
its target when present in a disulfide-bridged dimeric conformation. 
Utilizing its small size and dual binding specificities, ABDz1 has been 
used as an affinity fusion tag for an effective orthogonal affinity 
purification strategy [52,53].  
The bispecific library has also been screened for binders to tumor 
necrosis factor alpha (TNF-α) [54]. An initial phage display selection 
identified two bispecific variants, one of which bound TNF-α with a 
moderate affinity (385 nM apparent affinity) and HSA only weakly 
(1.9 µM) while the other variant bound strongly to HSA (17 nM) 
but only weakly to TNF-α (1.6 µM). These results pointed toward 
the challenge of obtaining two high affinity interactions in the same 
small protein domain. To explore this subject further, an affinity 
maturation library was designed based on the sequences of the two 
initial hits. Eight of the initial eleven residues were re-randomized and 
the library was expressed and displayed on the surface of 
staphylococcal cells to allow for multi-parameter fluorescence-
activated cell sorting. In these selections the library was screened for 
binders to TNF-α and, in a parallel selection, cells binding both 
TNF-α and HSA in the same sorting cycle were enriched using an 
additional fluorescent label. Characterization of variants from both 
selection strategies, illustrated by ABDT001 selected against TNF-α and 
ABDHT014 selected against TNF-α and HSA simultaneously (Figure 
4), demonstrated that affinities in the nanomolar range for both 
targets could be achieved (apparent affinities of 3-5 nM for TNF-α 
and KD down to 35 nM for HSA) and that the affinity maturation 
resulted in a roughly 100-fold improved TNF-α-binding. An 
interesting finding in the variants selected for TNF-α and HSA was a 
common, charge-switching, K36E substitution that was also observed 
during affinity maturation of G148-ABD for HSA [44]. However, 
none of the diversified residues reverted to the wild-type amino acid 
in any of the common clones identified after the dual selections.  
In an effort to expand the single domain bispecific concept to a 
cancer-related target protein, binders to the epidermal growth factor 
receptor 3 (HER3) have been selected [55]. In contrast to previous 
selections, phage display panning on this target generated more than 
30 unique but highly similar variants, represented by the strongest 
binder ABDHER3-3 in figure 4. All analyzed candidates bound HER3 
with affinities in the nanomolar range and all retained a strong, or 
even improved, binding to HSA (for example, ABDHER3-3 binds 
HER3 with a KD of 10 nM and HSA with 0.4 nM). The binding site 
on HER3 was shown to overlap with its ligand-binding site, 
indicating a potential anti-proliferative effect on HER3-
overexpressing cells. Currently, variants with sub-nanomolar affinity 
for both their target protein and HSA are under development 
(unpublished data). Together, these selections demonstrate that 
albumin binding can be retained despite randomization of a large 
number of residues in helix one and three. Up till now no binders 
with ability to bind albumin and the target simultaneously have been 
identified and no selections have been designed to address this 
property. Presumably, simultaneous binding would require a specific 
geometry of the target and the binding epitope in relation to the 
albumin-binding site, which has not yet been fulfilled for the currently 
evaluated target proteins. 
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Albumin-binding domains in folding studies 
 
Albumin-binding domains and other small domains have proven 
to be attractive model systems for experimental and theoretical 
folding studies [16,56,57]. For example, studies of engineered 
proteins that can switch folds provide insights into how new folds 
evolve and also demonstrate that latent structural information can be 
encoded in an amino acid sequence. Directed evolution of the 
immunoglobulin-binding domains of SPG and staphylococcal protein 
A has been used to generate pairs of monomeric proteins with a high 
degree of sequence identity but with different tertiary structures 
[58,59]. A similar effort has subsequently been devoted to designing 
pairs of proteins with very high sequence similarity, different folds 
and also different binding functions. Here, the starting points were 56 
residue polypeptides encoding non-homologous albumin- and 
immunoglobulin binding domains derived from SPG [60] (Figure 5). 
The albumin-binding domain used in this study was PSD-1 [34], the 
additional residues required to form the immunoglobulin-binding 
fold are located in the termini and are disordered in the 3α-fold of 
PSD-1. The first step in the process of making the two proteins more 
similar to each other was to encode latent binding sites for IgG in 
PSD-1 and for HSA in the 4ß+α IgG-binding protein, while 
preserving their structures and original binding functions. This 
resulted in a pair of proteins with 30 % identity, the albumin-binding 
GA30 and the immunoglobulin-binding GB30 (Figure 5). Next, the 
binary sequence space that separated these two sequences was reduced 
in a step-wise manner to generate variants of even higher sequence 
identity. Pairs with 77 % and 88 % identity were generated and 
NMR-analysis showed that the two folds were retained in all four 
variants (i.e. GA77 and GB77 or GA88 and GB88; Figure 5). The IgG-
binding was functional only in the 4ß+α fold and the HSA-binding 
only in the 3α-fold. Thus, this protein engineering endeavor 
demonstrated that as few as seven residues that differed between GA88 
and GB88 could determine both the fold and function of the domains.  
 
 
 
 
 
 
 
 
 
 
 
Analysis of the geometries of the non-identical residues in NMR-
structures of GA88 and GB88 facilitated the design of a new pair of 
sequences with an impressive 95 % identity (GA95 and GB95; Figure 
5) [61]. Structures of GA95 and GB95, which only differ in three 
positions, demonstrated that a single amino acid substitution could 
cause a conformational switch between the two functionally diverse 
folds [62]. A following study determined the NMR-structures of a 
series of variants, which only differed by one amino acid, and 
identified three mutational tipping points (L20A, T25I and L45Y) 
that shifted the equilibrium between the two possible folds [63]. 
These studies illustrate the exceptional mutational tolerance of the 
albumin-binding domains. Moreover, the data form the basis for a 
plausible hypothesis regarding the evolution of new protein structures 
and functions. Perhaps a duplicated albumin-binding domain acquired 
the immunoglobulin-binding fold in the multi-domain bacterial 
surface protein, where the multiple domain copies could allow the 
evolution of such gain of functionality without any significant loss of 
fitness [63,64].  
 
Summary and outlook 
 
Despite the small size, albumin-binding domains have successfully 
been engineered for several purposes. To date, more than a hundred 
engineered variants with altered specificity, improved affinity or 
stability and even new binding specificities have been reported. Large 
libraries of domains with diversified surface patches or shuffled 
homologous sequences have been displayed on phages, on ribosomes 
and on the surfaces of bacterial cells to facilitate in vitro selection of 
desired variants. Even though more than 50 % of the residues have 
been substituted in these efforts, many generated variants retain the 
favorable fold and stability of the original domain. Several beneficial 
sequence modifications have been discovered and structurally 
important residues that cannot easily be modified have been 
identified. The current detailed understanding of this defined 
sequence space provides a basis for further protein engineering efforts. 
Promising characteristics found in engineered domains might be 
combined and structural characterization of more variants would be 
useful for future efforts in this direction. Clever protein engineering 
strategies applied to a small protein domain with favorable 
biophysical properties such as the albumin-binding domain provides 
many exciting future opportunities for biophysicists or 
bioinformaticians engaged in the relationships between sequence, 
structure and function of proteins, as well as for protein engineers 
interested in new therapeutic applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Sequence alignment of very similar variants with different 
tertiary structures. Identical residues are shown in gray and differences 
are highlighted in color. The top five sequences form three-helix bundles 
(illustrated using the PDB-file 1GJT) and the lower five sequences form 
4ß+α folds (PDB-file 1FCC). Elements of secondary structure are indicated 
above the sequences. The figure is based on an alignment in Shen et al. 
[65] and was generated with Geneious Pro version 5.5.7.  
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